Search hospitals > Iowa > Sioux City
Siouxland Regional Cancer Center
Claim this profileSioux City, Iowa 51101
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Lymphoma
Conducts research for Non-Small Cell Lung Cancer
518 reported clinical trials
1 medical researcher
Summary
Siouxland Regional Cancer Center is a medical facility located in Sioux City, Iowa. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Lymphoma, Non-Small Cell Lung Cancer and other specialties. Siouxland Regional Cancer Center is involved with conducting 518 clinical trials across 405 conditions. There are 1 research doctors associated with this hospital, such as Donald Wender.Area of expertise
1Breast Cancer
Global LeaderER positive
PR positive
HER2 positive
2Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Clinical Trials running at Siouxland Regional Cancer Center
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Multiple Myeloma
Follicular Lymphoma
Cancer
Plasma Cell Neoplasms
Squamous Cell Carcinoma
ALK Gene Rearrangement
Lymphoma
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
TPIV100 + Sargramostim
for Breast Cancer
This trial tests a vaccine and a drug in patients with a specific type of breast cancer who still have cancer after chemotherapy. The vaccine helps the immune system target cancer cells, and the drug boosts white blood cells to strengthen this response. The goal is to see if this combination can better treat these patients.
Recruiting0 awards Phase 238 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Siouxland Regional Cancer Center?
Siouxland Regional Cancer Center is a medical facility located in Sioux City, Iowa. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Lymphoma, Non-Small Cell Lung Cancer and other specialties. Siouxland Regional Cancer Center is involved with conducting 518 clinical trials across 405 conditions. There are 1 research doctors associated with this hospital, such as Donald Wender.
Where is Siouxland Regional Cancer Center located?
**Siouxland Regional Cancer Center**
- **Address:** 230 Nebraska St, Sioux City, IA 51101
- **Affiliation:** Part of the Nylen Cancer Center
- **Services:** Offers personalized treatment plans, advanced services, and compassionate care for cancer and blood disorders.
Who should I call to ask about financial aid or insurance network?
**Siouxland Regional Cancer Center - Financial Assistance and Insurance Contacts**
- **Financial Navigator:** Traci Bates
- **Email:** batest@jencc.com
- **Phone:** (712) 252-9352
- **Patient Financial Services:**
- **Phone:** 833-961-2453
For inquiries regarding financial assistance, insurance, and billing for cancer treatment, please reach out to the contacts provided.
What insurance does Siouxland Regional Cancer Center accept?
The Siouxland Regional Cancer Center, part of MercyOne, accepts various insurance plans, though coverage may vary by location. For details on accepted insurance plans, contact the patient financial services department at 866-494-3001. Note that coverage for specific services or treatments may differ, and patients are responsible for their medical expenses.
What awards or recognition has Siouxland Regional Cancer Center received?
The Siouxland Regional Cancer Center, known as the June E. Nylen Cancer Center, is recognized for high-quality cancer care by the largest oncology association in the United States. It is part of the National Cancer Institute's Community Oncology Research Program (NCORP), highlighting its commitment to research and innovation in cancer care.